氨甲酸,乙基(3-羟基丙基)-,1,1-二甲基乙基酯 | 182951-96-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 氨甲酸,乙基(3-羟基丙基)-,1,1-二甲基乙基酯
• 英文名称: tert-butyl ethyl-(3-hydroxypropyl)carbamate
• 英文别名: 3-(N-BOC-ethylamino)-1-propanol；tert-Butyl ethyl3-hydroxypropylcarbamate；tert-butyl N-ethyl-N-(3-hydroxypropyl)carbamate
• CAS: 182951-96-8
• 化学式: C₁₀H₂₁NO₃
• 分子量: 203.282
• InChiKey: OHZRRDGESNRYIJ-UHFFFAOYSA-N

物化性质

• 沸点：
  288.8±19.0 °C(Predicted)
• 密度：
  1.006±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  氨甲酸,乙基(3-羟基丙基)-,1,1-二甲基乙基酯 在 N-溴代丁二酰亚胺(NBS) 、 三苯基膦 作用下， 以 正己烷 、 二氯甲烷 为溶剂， 生成 N-BOC-N-ethyl-3-bromo-propylamine
  参考文献：
  名称：

  Piperidinyl-2-alkyl, substituted linear polyamines for the reduction of

  摘要：

  本发明涉及式(I)的化合物 ##STR1## 其中，R.sub.1为氢，R.sub.2为较低的烷基、烯基或炔基；m为3或4，n为2或3；或者R.sub.1和R.sub.2共同为四乙烯基，m为3或4，n为2；或其盐。式(I)的化合物影响多胺生物合成，具有抗增殖活性以及对原虫的作用。

  公开号：

  US05834486A1
• 作为产物：
  描述：

  二碳酸二叔丁酯 、 3-(乙基氨基)-1-丙醇 在 甲醇 、 氨 作用下， 以 二氯甲烷 为溶剂， 反应 15.75h， 生成 氨甲酸,乙基(3-羟基丙基)-,1,1-二甲基乙基酯
  参考文献：
  名称：

  Piperidinyl-2-alkyl, substituted linear polyamines for the reduction of

  摘要：

  本发明涉及式（I）的化合物##STR1## 其中，R.sub.1为氢，R.sub.2为较低的烷基、烯基或炔基，m为3或4，n为2或3；或R.sub.1和R.sub.2共同为四乙烯，m为3或4，n为2；或其盐。公式（I）的化合物影响多胺生物合成，并具有抗增殖活性以及对原生动物的作用。

  公开号：

  US05834486A1

文献信息

• [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS
  申请人：INFLAZOME LTD

  公开号：WO2019068772A1

  公开（公告）日：2019-04-11

  The present invention relates to compounds of formula (I): wherein Q is selected from O or S; R1 is a saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include cyclic groups, wherein the hydrocarbyl group may optionally be substituted, and wherein the hydrocarbyl group may optionally include one or more heteroatoms N, O or S in its carbon skeleton; and R2 is a cyclic group substituted at the a-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.

  本发明涉及以下式(I)的化合物：其中Q从O或S中选择；R1是饱和或不饱和的烃基团，其中烃基团可以是直链或支链的，或者包括环状基团，其中烃基团可以选择性地被取代，并且其中烃基团的碳骨架中可以选择性地包含一个或多个杂原子N、O或S；以及R2是在α位取代的环状基团，其中R2可以选择性地进一步取代。本发明还涉及这些化合物的盐、溶剂合物和前药，包括这些化合物的药物组合物，以及利用这些化合物治疗和预防医学疾病和疾病的用途，尤其是通过抑制NLRP3。
• Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient
  申请人：Moriya Minoru

  公开号：US20060106046A1

  公开（公告）日：2006-05-18

  The invention provides melanin-concentrating hormone receptor antagonists containing as the active ingredient piperidine derivatives represented by the general formula [I]: [wherein R 1 is hydrogen, hydroxyl, lower alkyl, or the like; R 2 , R 3a , R 3b , R 4a , R 4b , R 5a , R 5b and R 6 each stands for hydrogen, halogen, or the like; W 1 and W 2 each independently stands for —O—, —CH 2 —, or the like; Y 1 , Y 2 , Y 3 and Y 4 stand for —CH—, —CF—, —N—, or the like; Z stands for lower alkyl, an aliphatic heterocyclic group, or the like; Ar is a mono- or bi-cyclic aliphatic heterocycle or an aromatic heterocycle; and n is an integer of 1 to 8]. The compounds act as antagonist against melanin-concentrating hormone receptor and are useful as drugs for central diseases, circulatory diseases, or metabolic diseases.

  本发明提供一种含有作为活性成分的吡啶衍生物的黑色素浓集激素受体拮抗剂，其通式表示为[I]：[其中R1为氢、羟基、低级烷基或类似物；R2、R3a、R3b、R4a、R4b、R5a、R5b和R6各自代表氢、卤素或类似物；W1和W2各自独立地代表—O—、—CH2—或类似物；Y1、Y2、Y3和Y4代表—CH—、—CF—、—N—或类似物；Z代表低级烷基、脂环族杂环基或类似物；Ar为单环或双环脂环族杂环或芳香族杂环；n为1至8的整数]。这些化合物作为黑色素浓集激素受体的拮抗剂，并且可用于中枢疾病、循环系统疾病或代谢性疾病的药物。
• Water-Soluble Prodrugs of Florfenicol and its Analogs
  申请人：Glinka Tomasz W.

  公开号：US20080188556A1

  公开（公告）日：2008-08-07

  The present invention discloses certain novel prodrugs of florfenicol and/or of florfenicol analogs, including prodrugs of salts pharmaceutically acceptable salts of florfenicol and its analogs, including nitrogen-containing esters of the secondary alcohol group of florfenicol and of its analogs, and pharmaceutically acceptable salts thereof, compositions containing them, and methods of administering them to subjects. In particular embodiments the prodrugs are sufficiently water-soluble to serve the functions needed of a water-soluble prodrug of florfenicol or of a water-soluble prodrug of a florfenicol analog. A certain subclass of the compounds also possesses the hydrolytic stability needed to maintain the prodrug in solution in the subject's system until appropriate conditions exist when the prodrug can hydrolyze, releasing florfenicol or the florfenicol analog in question.

  本发明揭示了某些新型氟苯菲酚和/或氟苯菲酚类似物的前药，包括氟苯菲酚及其类似物的可接受药用盐的前药，包括氟苯菲酚和其类似物的次级醇基的含氮酯前药及其药用可接受盐，含有它们的组合物以及将它们用于给予受试者的方法。在特定实施例中，这些前药具有足够的水溶性，以发挥氟苯菲酚或氟苯菲酚类似物的水溶性前药所需的功能。某些化合物的亚类也具有水解稳定性，以保持前药在受试者的系统中溶解，直到存在适当的条件使前药水解，释放所需的氟苯菲酚或氟苯菲酚类似物。
• Water-soluble prodrugs of florfenicol and its analogs
  申请人：Intervet Inc.

  公开号：US08084643B2

  公开（公告）日：2011-12-27

  The present invention discloses certain novel prodrugs of florfenicol and/or of florfenicol analogs, including prodrugs of salts pharmaceutically acceptable salts of florfenicol and its analogs, including nitrogen-containing esters of the secondary alcohol group of florfenicol and of its analogs, and pharmaceutically acceptable salts thereof, compositions containing them, and methods of administering them to subjects. In particular embodiments the prodrugs are sufficiently water-soluble to serve the functions needed of a water-soluble prodrug of florfenicol or of a water-soluble prodrug of a florfenicol analog. A certain subclass of the compounds also possesses the hydrolytic stability needed to maintain the prodrug in solution in the subject's system until appropriate conditions exist when the prodrug can hydrolyze, releasing florfenicol or the florfenicol analog in question.

  本发明揭示了某些新颖的氟苯菲酮和/或氟苯菲酮类似物的前药，包括氟苯菲酮及其类似物的盐的前药，包括氟苯菲酮及其类似物次级醇基的含氮酯前药及其药学上可接受的盐，含有它们的组合物以及将它们用于主体的方法。在特定实施例中，这些前药具有足够的水溶性，以满足氟苯菲酮或氟苯菲酮类似物的水溶性前药所需的功能。某些化合物的一个子类还具有水解稳定性，以维持前药在主体系统中的溶解度，直到存在适当的条件时，前药才能水解，释放所需的氟苯菲酮或氟苯菲酮类似物。
• MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS CONTAINING PIPERIDINE DERIVATIVES AS THE ACTIVE INGREDIENT
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP1595867A1

  公开（公告）日：2005-11-16

  The invention provides melanin-concentrating hormone receptor antagonists containing as the active ingredient piperidine derivatives represented by the general formula [I]:    [wherein R1 is hydrogen, hydroxyl, lower alkyl, or the like; R2, R3a, R3b, R4a, R4b, R5a, R5b and R6 each stands for hydrogen, halogen, or the like; W1 and W2 each independently stands for -O-, -CH2-, or the like; Y1, Y2, Y3 and Y4 stand for -CH-, -CF-, -N-, or the like; Z stands for lower alkyl, an aliphatic heterocyclic group, or the like; Ar is a mono- or bi-cyclic aliphatic heterocycle or an aromatic heterocycle; and n is an integer of 1 to 8]. The compounds act as antagonist against melanin-concentrating hormone receptor and are useful as drugs for central diseases, circulatory diseases, or metabolic diseases.

  本发明提供了含有通式[I]代表的哌啶衍生物作为活性成分的黑色素浓缩激素受体拮抗剂： [其中R1为氢、羟基、低级烷基或类似物；R2、R3a、R3b、R4a、R4b、R5a、R5b和R6各自代表氢、卤素或类似物；W1和W2各自独立地代表-O-、-CH2-或类似物；Y1、Y2、Y3 和 Y4 分别代表-CH-、-CF-、-N-或类似物；Z 代表低级烷基、脂族杂环基团或类似物；Ar 是单环或双环脂族杂环或芳香族杂环；以及 n 是 1 至 8 的整数]。这些化合物是黑色素浓缩激素受体的拮抗剂，可作为治疗中枢疾病、循环系统疾病或代谢疾病的药物。